Neovascular Glaucoma

2

Review clinical trials related to Neovascular Glaucoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma

The goal of this observational study is to quantify iris blood flow via non-invasive eye scanning for evaluating ocular lesions in adults aged 18 years and older, including healthy volunteers, patients with type 2 diabetes mellitus (T2DM) without fundus lesions, T2DM patients with diabetic retinopathy (DR), and T2DM patients complicated with both DR and neovascular glaucoma (NVG). The main questions it aims to answer are: * Does iris blood flow fraction at six pupillary quadrants differ significantly among people with different stages of type 2 diabetic eye complications? * Are there quadrant-specific and gender-based differences in iris microcirculation changes caused by diabetic eye diseases? If there is a comparison group: Researchers will compare iris blood flow data from four groups (healthy controls, T2DM without DR, T2DM with DR, T2DM with DR + NVG) to see how iris blood circulation changes as diabetic eye conditions get worse, and test whether iris blood flow indicators can help identify patients with neovascular glaucoma. Participants will complete the following tasks: * Provide basic personal information, past medical history and recent laboratory test results from their routine medical records; * Receive a painless, non-invasive iris OCTA eye scan to capture iris blood flow images at six quadrants around the pupil.

Participants needed: 98
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Qilu Hospital of Shandong UniversityUpdated: Jul 28, 2026Locations: 1Duration: 2 Weeks
Eligibility criteria

Aged ≥ 18 years of age, regardless of gender, with or without type 2 diabetes me... [+3]

The studied eye suffers from other ocular diseases that may interfere with exami... [+2]

Status: Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment. The objective of this study is to assess safety and effectiveness of Eylea using in real clinical practice. Patients will be followed for a time period of 6 months from start of Eylea treatment or until it is no longer possible (e.g. lost to follow-up). In total, 480 patients will be recruited. For each patient, data are collected as defined in the electronic case report form (eCRF) at the initial visit, follow-up visit and final visit, either by routine clinical visits (as per investigators routine practice).

Participants needed: 480
Trial details
Biological sex: AllType: ObservationalSponsor: BayerUpdated: Jun 30, 2026Locations: 1
Eligibility criteria

Diagnosis of NVG [+1]

Patients who are contraindicated based on approved label [+1]